Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IGNK002
- Development stage
- Unknown
- Lead developer
- Ingenium Therapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
IGNK002 is an allogeneic, off-the-shelf memory natural killer (NK) cell therapy being developed by Ingenium Therapeutics. As a non-engineered cellular immunotherapy, it utilizes memory NK cells which are characterized by enhanced expression of activating receptors and superior persistence compared to conventional NK cells. The therapy is specifically designed for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC). A significant feature of IGNK002 is its off-the-shelf formulation, which has successfully completed 24-month freeze/thaw stability testing, facilitating scalable manufacturing and immediate clinical availability.
- Other names
- Memory NK (IGNK002)
Beyond the preview
Go deeper on IGNK002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IGNK002.